ArticlePharmacoEconomics2016

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.

Jonathan Graham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.